Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in AS patients undergoing TAVR
NCT05241431Phase 3Unknown
- Sponsor
- Aarhus University
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aortic stenosis (AS) and heart failure (HF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Composite endpoint of changes in LV mass, systolic function, eGFR, and serum Nt-proBNP at 12 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
aortic stenosis (AS)heart failure (HF)
Beyond the preview
Go deeper on NCT05241431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241431.